SQUAWK/NEWS
Account
Theme
Account
Menu
Live News MNA ARTICLE M impact

Qyuns Therapeutics Licenses Antibody Program to Caldera

Qyuns Therapeutics said it is licensing an early-stage antibody program to US biotech Caldera Therapeutics in a deal worth up to $750 million plus an upfront fee.

2509
SquawkNews Desk

Qyuns Therapeutics HKEX:2509 is licensing an early-stage antibody program to US biotech Caldera Therapeutics in a deal worth up to $750 million plus an upfront fee, the Hong Kong-listed firm said on Thursday.Here are some details

Related stories

Wendy’s Rejects $1.4 Billion Buyout Bid, Adopts Poison Pill Wendy’s rejected a $1.4 billion buyout offer from an activist investor and adopted a poison pill plan. M impact | MNA | Nov 05, 2026, 02:05 PM UTC Critical Metals Completes Acquisition of European Lithium M impact | MNA | Nov 05, 2026, 02:01 PM UTC Azimut Expects FSI Authorization Filing for Fintech Bank Transaction Azimut said FSI is expected to file an authorization request with the Bank of Italy to proceed with a transaction intended to create a new fintech bank. The supplied report says th L impact | MNA | Nov 05, 2026, 01:57 PM UTC BHAV Acquisition Agreement Values Nemi at $400M Pre-Money The business combination agreement sets Nemi's pre-money equity value at $400 million, or 40 million shares at $10 per share. M impact | MNA | Nov 05, 2026, 01:48 PM UTC Forge Nano Completes HZO Acquisition in All-Stock Deal Forge Nano completed its acquisition of HZO in an all-stock deal, combining atomic-scale deposition technology with high-volume protective coating capabilities. M impact | MNA | Nov 05, 2026, 01:35 PM UTC Mufin Green Finance Approves 23% Bimapay Finsure Stake Purchase Mufin Green Finance approved the acquisition of a 23% equity stake in Bimapay Finsure for 657.5 million rupees. M impact | MNA | Nov 05, 2026, 01:14 PM UTC